Skip to main content
Log in

Predictors of Bleeding Complications After Rescue Coronary Interventions

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

The purpose of this study was to determine predictors of bleeding complications after current rescue coronary interventions including stenting and adjunctive platelet inhibitors. Previous studies of rescue angioplasty for thrombolytic failure have identified variable rates of bleeding complications with balloon angioplasty alone. Although coronary stents and glycoprotein 2b/3a inhibitors have been shown to improve outcome in a wide variety of coronary interventions, the impact of these therapies on bleeding complications after rescue coronary intervention has not been determined. From 1996 through 1998, we treated 108 consecutive patients with rescue coronary intervention (defined as attempted coronary intervention within 12 hours of thrombolysis for ongoing symptoms or electrocardiogram [ECG] changes) including conventional percutaneous transluminal coronary artery (PTCA), stenting (n=45), and glycoprotein 2b/3a inhibitor use (n=31). In-hospital clinical outcomes were obtained in all patients, and univariate and multivariate predictors of bleeding complications were identified. In hospital, moderate to severe bleeding complications occurred in 17.6% of the cohort, but the rate of severe bleeding complications (2.7%) and vascular repair (1.9%) were low. Independent predictors of bleeding complications were age >60y, female gender, cardiogenic shock, and streptokinase use. Neither the delayed use of abciximab (on average 4 hours after thrombolytic therapy initiation) nor the use of rescue stenting were predictors of increased moderate to severe bleeding complications. Current rescue coronary intervention, including stents and platelet inhibitors, is associated with a low rate of severe bleeding complications. Moderate to severe bleeding complications were more common in selected subgroups of patients but not increased significantly by stenting or delayed abciximab use.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-1622.

    Google Scholar 

  2. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction Lancet 1992;339:753-770.

    Google Scholar 

  3. den Heijer P, Vermeer F, Ambrosioni E, et al. Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: A double-blind, randomized angiographic trial of lanoteplase versus alteplase. Circulation 1998;98:2117-2125.

    Google Scholar 

  4. Grines CL. Should thrombolysis or primary angioplasty be the treatment of choice for acute myocardial infarction? Primary angioplasty – the strategy of choice. N Engl J Med 1996;335:1313-1316; discussion 1316-1317.

    Google Scholar 

  5. O'Neill WW, Weintraub R, Grines CL, et al. A prospective, placebo-controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy of acute myocardial infarction. Circulation 1992;86:1710-1717.

    Google Scholar 

  6. Rogers WJ, Baim DS, Gore JM, et al. Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator. Results of the thrombolysis in myocardial infarction (TIMI) phase II-A trial. Circulation 1990;81:1457-1476.

    Google Scholar 

  7. Ross AM, Lundergan CF, Rohrbeck SC, et al. Rescue angioplasty after failed thrombolysis: Technical and clinical outcomes in a large thrombolysis trial. GUSTO-1 Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1998;31:1511-1517.

    Google Scholar 

  8. The EPISTENT Investigators. Randomised placebocontrolled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998;352:87-92.

    Google Scholar 

  9. Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998;98:734-741.

    Google Scholar 

  10. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.

    Google Scholar 

  11. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998;339:436-443.

    Google Scholar 

  12. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501.

    Google Scholar 

  13. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994;331:489-495.

    Google Scholar 

  14. Antoniucci D, Santoro GM, Bolognese L, Valenti R, Trapani M, Fazzini PF. A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction: Results from the Florence randomized elective stenting in acute coronary occlusions (FRESCO) trial. J Am Coll Cardiol 1998;31:1234-1239.

    Google Scholar 

  15. Stone GW, Brodie BR, Griffin JJ, et al. Clinical and angiographic follow-up after primary stenting in acute myocardial infarction: The primary angioplasty in myocardial infarction (PAMI) stent pilot trial. Circulation 1999;99:1548-1554.

    Google Scholar 

  16. Sundlof DW, Rerkpattanapitat P, Wongpraparut N, et al. Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty. Am J Cardiol 1999;83:1569-1571, A7.

    Google Scholar 

  17. Moreno R, Garcia E, Abeytua M, et al. Coronary stenting during rescue angioplasty after failed thrombolysis. Cathet Cardiovasc Interv 1999;47:1-5.

    Google Scholar 

  18. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 1998;339: 1665-1671.

    Google Scholar 

  19. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997;336:1621-1628.

  20. Juliard JM, Himbert D, Cristofini P, et al. A matched comparison of the combination of prehospital thrombolysis and standby rescue angioplasty with primary angioplasty. Am J Cardiol 1999;83:305-310.

    Google Scholar 

  21. Stone GW, Brodie BR, Griffin JJ, et al. Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: inhospital and 30-day results of the PAMI stent pilot trial. Primary Angioplasty in Myocardial Infarction Stent Pilot Trial Investigators. J Am Coll Cardiol 1998;31:23-30.

    Google Scholar 

  22. Marder VJ, Sherry S. Thrombolytic therapy: Current status (2). N Engl J Med 1988;318:1585-1595.

    Google Scholar 

  23. Marder VJ, Sherry S. Thrombolytic therapy: Current status (1). N Engl J Med 1988;318:1512-1520.

    Google Scholar 

  24. Alpert JS. Importance of the pharmacological profile of thrombolytic agents in clinical practice. Am J Cardiol 1991;68:3E-7E.

    Google Scholar 

  25. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation 1999;99:2720-2732.

    Google Scholar 

  26. Mandak JS, Blankenship JC, Gardner LH, Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to minimize platelet aggregation and coronary thrombosis. J Am Coll Cardiol 1998;31:1518-1524.

    Google Scholar 

  27. The EPIC Investigation. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dauerman, H.L., Andreou, C., Perras, M.A. et al. Predictors of Bleeding Complications After Rescue Coronary Interventions. J Thromb Thrombolysis 10, 83–88 (2000). https://doi.org/10.1023/A:1018759024035

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1018759024035

Navigation